Amgen Shadow Pricing Of Enbrel Under Scrutiny At US House Hearing

 
• By Jessica Merrill

Amgen CEO Bradway told Congress the biggest driver of list pricing for Enbrel has been the need to match the price of AbbVie's Humira to secure formulary access.

Shadow
US Congress took issue with industry "shadow pricing" • Source: Shutterstock

More from Pricing Debate

More from Market Access